AmpliPhi acquires key bacteriophage assets from UK-based Novolytics

The assets will broaden AmpliPhi's IP portfolio and speed the development of its phage therapies

M. Scott Salka, CEO of AmpliPhi Biosciences, said: “These Novolytics assets will broaden our IP portfolio and speed the development of our phage therapies. This acquisition supports our strategy of assembling the premier bacteriophage therapy company through the acquisition of world-class talent and assets to accomplish our goal of arming physicians and patients with novel and effective weapons against the growing threat of antibiotic-resistant pathogens.”